|
No need to choose between embryonic and adult stem cells -- Advanced Cell Technology (ACT) works with both to develop cellular therapies designed to regenerate human tissue. The company has developed three product platforms based on stem-cell technology. They are retinal pigment epithelial therapy (RPE) for the treatment of degenerative retinal disease; myoblast stem cell therapy to treat chronic heart failure and other heart problems; and the hemangioblast platform (HG) for the treatment of blood and cardiovascular diseases. Though the company is focused on bringing the clinical-stage technologies to market, it is also continuing to conduct research for other regenerative medicine treatments.
|
| | | Contact Information | |
Address: |
381 Plantation St.
Worcester, MA 01605
| | Phone: | 508-756-1212 | | Fax: | 508-756-4468 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 0.80 M | | Revenue Growth (1 yr): | 21.60% | | Employees (2008): | 12 | | Employee Growth (1 yr): | (-75.00%) |
|
|
Key People
| | • |
Chairman and CEO:
William M. (Bill) Caldwell IV
| | • |
Director Operations:
Rita Parker
|
|
|
